Top depression articles of 2016

Major depression has the heaviest burden of disability among mental and behavioral disorders, according to WHO.

Specifically, major depression accounts for 3.7% of all U.S. disability-adjusted life years and 8.3% of all U.S. years lived with disability.

As 2016 comes to a close, Healio Psychiatry collected the top 5 depression articles of the year.

Antidepressant Brintellix renamed Trintellix to avoid confusion in US

Brintellix, a vortioxetine product approved to treat major depressive disorder in adults, will be marketed in the United States under a new name, Trintellix, starting in June 2016, according to a company press release. Read more

Latuda effective, well-tolerated among adults with major depressive disorder

TORONTO — According to phase 3 study results presented here, Latuda, an atypical antipsychotic agent, significantly reduced depressive symptoms among adults with major depressive disorder with limited manic symptoms. Read more

Mortality, hospitalizations increase following FDA-issued citalopram warning

Reduction of prescribed citalopram dosages to a new safety limit was associated with significantly higher rates of hospitalization and mortality in a large veteran patient population previously treated with higher dosages. Read more

Latuda improves depression, sexual functioning in depression with mixed features

PHILADELPHIA — Latuda, an atypical antipsychotic currently intended for schizophrenia and bipolar I disorder, improved depressive symptoms and sexual functioning among individuals with major depressive disorder with mixed features, according to data presented here. Read more

Depressive episodes increase nationally among adolescents, young adults

Analysis of nationally representative data indicated a significant increase in prevalence of major depressive episodes within the last year among adolescents and young adults. Read more